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COVID-19: Viral origins, vaccine fears and risk perceptions 
On 30 March 2021, the Joint WHO-China mission investigating the origins of the SARS-CoV-2 virus 
released their much awaited report.1 For some, it was an anti-climax as the source still remains 
unknown, and others were concerned that the assessment was not extensive enough. The WHO’s 
Director General, Dr Tedros Ghebrejesus, remarked that further data and studies was still needed and 
that “all hypotheses remain on the table”.2  
So what have we learned? Firstly, the likeliest explanation is that the virus spilled over from its animal 
reservoir (Rhilophilus bats) to humans, possibly through an intermediate animal host that has not been 
identified. This would be in keeping with the zoonotic origins of SARS-CoV-2’s other coronavirus cousins 
(the four human coronaviruses, MERSCoV2 and SARS-CoV). This highlights the need for enhanced 
biosecurity measures globally if we are to track and prevent the spread of new zoonotic pathogens to 
human populations.3 This will require greater international collaboration, sharing of intelligence, as well 
as epidemiological, zoonotic and genomic surveillance.4 It also highlights the ongoing risks at the 
human-wildlife interface such as in farmed wild animals, live animal markets and wet markets where the 
potential for transmission is increased.5 We also learned that certain settings can act as amplification 
sites, as was the case with the Wuhan wet market, that was initially thought to be the source but now 
looks likely to have been where there was an amplification effect and superspreading.6 
Unsurprisingly, the inability of the scientific mission to find a conclusive source has helped to maintain 
the conspiracy theory that the virus origins were from a laboratory rather than nature. This illustrates a 
perennial problem: scientists formulate theories and arrive at measured conclusions based on the 
strength of the evidence to hand. Where there is insufficient or inadequate evidence, their conclusions 
have to be more nuanced and caveated, and they express the uncertainties in keeping with scientific 
practice. However, for the public and media, the demand is for simple certainty, absolutes, that fit 
preferably in a headline or a social media tweet. Scientific uncertainty comes across as ambiguity and 
causes confusion.7 
On a related note, is the ongoing saga regarding the safety of the Oxford-AstraZeneca COVID Vaccine. Its 
roll out in Europe has been dogged by initially hesitance by some countries to deploy it on the grounds 
of insufficient safety or efficacy evidence. Most recently are the concerns of the association with a very 
rare condition, Cerebral Venous Sinus Thrombosis (CVST). Germany had observed 13 cases of CVST after 
1.6 million immunisation doses8 but the UK on the other hand has seen 50 cases of CVST from 20.6 
million vaccine doses given (as of 5 April 2021).9 One theory put forward is that this phenomenon is due 
to the vaccine triggering the development of an prothrombotic disorder caused by platelet-activating 
antibodies that clinically resembles heparin-induced thrombocytopenia.10 This is plausible, but has yet to 
be scientifically confirmed. The reason for the marked discrepancies in adverse event rates between 
countries is not clear although one possibility may be that most of the UK doses were given to older 
population groups where the likelihood of this event may be rarer. Similar fears have emerged for the 
Johnson & Johnson vaccine in recent weeks. 
However, association does not imply causation, nor are we certain at this juncture that it is a true signal. 
Even if this association turns out to be true, there is also a need to put the risks in context and 
communicate it effectively to the public and policymakers so that rationale conclusions are made. For 
example, the incidence of CVST after immunisation is roughly 8.1 per million doses in Germany and 1.2 
per million in the UK. Pre-COVID, the reported incidence of CVST is 2-5 per million population.11 The 
background incidence and possible immunisation-related incidence are therefore of similar magnitude. 
On the other hand, CVST has been recognized as a complication of SARS-CoV-2 infection.12 Moreover, 
the risk of death, assuming an infection fatality rate of 0.54%,13 is of the order of 54,000 deaths per 
million persons infected. In other words, the balance of benefit to harm with immunisation is strongly in 
favour of immunisation, a conclusion reached by both the World Health Organisation14 and European 
Medicines Agency15. The benefit of immunisations would be much greater in areas where there are high 
levels of infections. The risks therefore have to be placed in context. 
Unfortunately, public risk perception is fallible and susceptible to scare stories. The public are likely to 
fear the rarer and more exotic adverse events, and therefore overestimate low-probability but 
high-consequence risks that grab media attention. There is also the phenomenon of ambiguity aversion, 
where communicating scientific uncertainty decreases public perceptions of vaccine effectiveness and 
therefore interest in vaccination, and leads to a loss of trust in health officials.16  
At the present time when the virus continues to surge worldwide, with new epidemic waves from 
Poland to Brazil to India, there can be no room for vaccine hesitancy. The biggest risk for us all is the 
emergence of new viral variants that have acquired vaccine-escape that can undo the progress made so 
far in tackling the pandemic. There are already variants of concern that have emerged in South Africa 
(B.1.351 variant) and Brazil (P2 variant) that have shown reductions in vaccine efficacy, that is thus far 
thankfully limited.17 Neither is there a full-proof border control system that can keep infection out of a 
country indefinitely that does not entail crippling social and economic costs to the country. Finally, we 
will also need to address the important issue of global vaccine equity. If we want to get out of the 
pandemic’s stranglehold, we will need to get as many people vaccinated as we can everywhere and as 
soon as we can.  
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